Schrödinger at Leerink Conference: Strategic Growth Amid Transition

Schrödinger targets ACV growth of 10%–15% annually while reporting ACV and revenue of roughly $200M at end-2025; revenue is expected to decline in 2026 as the company shifts on-prem contracts to ratable hosted contracts. The firm has generated ~$650M in cash from collaborations over the past five years, plans to launch a predictive toxicology module this year, and is expanding materials/battery capabilities. Management expects revenue/ACV to stabilize over a three-year horizon and targets profitability by 2028, implying near-term headwinds but a constructive multi-year outlook driven by new modules, materials growth and recurring milestones/royalties.

Analysis

The accounting transition to ratable revenue recognition is a deliberate tradeoff: expect near-term headline revenue compression but materially cleaner forward visibility that should shorten investor debate about organic demand once the new cadence is embedded (6–18 months). That smoothing will compress reported growth in quarters with heavy bookings yet reduces forecast variance, which in turn can support multiple expansion if recurring contract metrics (renewal rates, net retention) track consistently higher.

Monetization of adjacent modules and deeper equity stakes in partner ventures converts episodic upside into longer-duration, higher-margin cashflows — think a gradual shift of revenue mix from transactional to annuity-like receipts over 2–4 years. The materials business behaves like a long-dated call option: meaningful upside if adoption accelerates but will likely remain a modest contributor until a multi-year cohort of adopters and industry-trained computational scientists materializes.

Key risks are asymmetric and timing-sensitive: a rapid advance in large-scale ML “foundational” chemistry models or accelerated regulatory skepticism around in-silico toxicology would erode the physics moat over 3–7 years; conversely, a steady cadence of milestone/royalty receipts or faster cross-selling into toxicology budgets would crystallize upside sooner. Monitor three near-term readouts as true inflection signals — renewal/NRR trends, first commercial uptake velocity for the new module, and schedule of milestone/royalty recognitions — any of which can flip the valuation trajectory within 12 months.

Key Decisions for Investors

• Buy SDGR shares (12–24 month horizon) on weakness tied to revenue-recognition optics; reward: re-rating as recurring revenue visibility improves and modules ramp (target +40–60%); risk: ~30–40% downside if ACV-like growth stalls — size position with a 6–8% portfolio allocation and scale in on Qs showing NRR >100%.
• Synthetic long via options (12–18 month call spread): buy ATM 12–18m SDGR calls and fund with higher-strike calls at ~1.5x to limit premium outlay; R/R favorable if the market awards a SaaS multiple within one year while capping total premium loss to <100% of paid debit.
• Hedge/paired trade (12 months): long SDGR / short speculative AI-driven discovery peer (e.g., RXRX) in a 1:1 notional pair to isolate re-rating of durable physics-based franchises vs. hype names; expect outperformance if recurring revenue metrics and partner royalties begin to compound — downside if broad market derates cyclicals.
• Protective hedges around milestone windows: buy 6–9 month puts at ~0.8x spot to cap downside around expected milestone/recognition quarters; cost is insurance against lumpy cash surprise and preserves upside exposure for catalysts.